Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix in female school students in Thailand
NCT03747770Unknown
- Sponsor
- International Vaccine Institute
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection, sponsored by International Vaccine Institute. Primary endpoint: HPV 16 and 18 infection prevalence at 4 years. Status: unknown.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03747770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747770.